A Phase 1b, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors
- Voskoboynik, Mark (Primary Chief Investigator (PCI))
- Hawkins, Cheryl-Ann (Project Manager)
Project: Research